WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Web Hosting Domain Name Industry Sunday, June 7, 2020 
Add Press Release News | News Feeds Feeds | Email This News Email

Global Stem Cell Partnering Deals Collection (2010-2020): Access to Headline, Upfront, Milestone and Royalty Data
Tuesday, May 26, 2020

DUBLIN, May 18, 2020 /PRNewswire/ -- The "Global Stem Cell Partnering Terms and Agreements 2010-2020" report has been added to's offering.

This report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies.

    --  Trends in Stem Cell dealmaking in the biopharma industry since 2010
    --  Analysis of Stem Cell deal structure
    --  Access to headline, upfront, milestone and royalty data
    --  Case studies of real-life Stem Cell deals
    --  Access to Stem Cell contract documents
    --  Leading Stem Cell deals by value since 2010
    --  Most active Stem Cell dealmakers since 2010

The report provides a detailed understanding and analysis of how and why companies enter Stem Cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Stem Cell agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Stem Cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Stem Cell partnering deals.

The report presents financial deal term values for Stem Cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Stem Cell partnering field; both the leading deal values and most active Stem Cell dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 600 online deal records of actual Stem Cell deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Stem Cell dealmaking.

    --  Chapter 1 provides an introduction to the report
    --  Chapter 2 provides an overview of the trends in Stem Cell dealmaking
        since 2010, including details of headline, upfront, milestone and
        royalty terms.
    --  Chapter 3 provides a review of the leading Stem Cell deals since 2010.
        Deals are listed by headline value. Where the deal has an agreement
        contract published at the SEC a link provides online access to the
    --  Chapter 4 provides a comprehensive listing of the top 25 most active
        companies in Stem Cell dealmaking with a brief summary followed by a
        comprehensive listing of Stem Cell deals announced by that company, as
        well as contract documents, where available.
    --  Chapter 5 provides a comprehensive and detailed review of Stem Cell
        partnering deals signed and announced since Jan 2010, where a contract
        document is available in the public domain. Each deal title links via
        Weblink to an online version of the deal record and contract document,
        providing easy access to each contract document on demand.
    --  Chapter 6 provides a comprehensive and detailed review of Stem Cell
        partnering deals signed and announced since Jan 2010. The - Chapter is
        organized by specific Stem Cell technology type. Each deal title links
        via Weblink to an online version of the deal record and where available,
        the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Stem Cell partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Stem Cell partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Stem Cell technologies and products.

Analyzing actual contract agreements allows assessment of the following:

    --  What are the precise rights granted or optioned?
    --  What is actually granted by the agreement to the partner company?
    --  What exclusivity is granted?
    --  What is the payment structure for the deal?
    --  How are sales and payments audited?
    --  What is the deal term?
    --  How are the key terms of the agreement defined?
    --  How are IPRs handled and owned?
    --  Who is responsible for commercialization?
    --  Who is responsible for development, supply, and manufacture?
    --  How is confidentiality and publication managed?
    --  How are disputes to be resolved?
    --  Under what conditions can the deal be terminated?
    --  What happens when there is a change of ownership?
    --  What sublicensing and subcontracting provisions have been agreed?
    --  Which boilerplate clauses does the company insist upon?
    --  Which boilerplate clauses appear to differ from partner to partner or
        deal type to deal type?
    --  Which jurisdiction does the company insist upon for agreement law?

Companies Mentioned

    --  A*STAR Agency for Science
    --  Technology and Research
    --  A*STAR Genome Institute of Singapore
    --  Accellta
    --  Access BIO
    --  Aelan Cell Technologies
    --  AGC Asahi Glass
    --  AiVita Biomedical
    --  Akron Biotechnology
    --  Allele Biotechnology and Pharmaceuticals
    --  American CryoStem
    --  American society of Hematology
    --  Angiocrine Bioscience
    --  Angionetics
    --  Angiostem
    --  Anthony Nolan
    --  Apceth
    --  Aratana Therapeutics
    --  Ascendance Biotechnology
    --  Astellas Pharma
    --  Asterand Bioscience
    --  Asterias Biotherapeutics
    --  AstraZeneca
    --  Athersys
    --  Australian Research Council
    --  Axcelead Drug Discovery Partners
    --  Axiogenesis
    --  AxoSim
    --  Bassett Salon Solutions
    --  Bayer USA Foundation
    --  Baylor Research Institute
    --  Beckman Research Institute of City of Hope
    --  Berlin-Brandenburg Center for Regenerative Therapies
    --  Be The Match BioTherapies
    --  Beyond Type 1
    --  Bio-Techne
    --  BioBridge Global
    --  BioCardia
    --  BioHeart
    --  Biological Industries
    --  Biomed
    --  BioRestorative Therapies
    --  Biosafe
    --  Biotech Products Services & Research
    --  BlueRock Therapeutics
    --  Boehringer Ingelheim
    --  BrainStorm Cell Therapeutics
    --  Brigham and Women's Hospital
    --  Caladrius Biosciences
    --  Calidi Biotherapeutics
    --  California Institute for Regenerative Medicine
    --  California State University
    --  California Stem Cell
    --  Calimmune
    --  Canadian National Transplant Research Program
    --  CareDx
    --  Case Western Reserve University
    --  CASI Pharmaceuticals
    --  Catalent Pharma Solutions
    --  Cedars-Sinai Medical Center
    --  Celgene
    --  Cell2in
    --  Cell Applications
    --  Cellaria Biosciences
    --  Cell Care Therapeutics
    --  Cellect Biotechnology
    --  Cellectricon
    --  Celling Biosciences
    --  CellProThera
    --  Celltex Therapeutics
    --  Cell Therapy Catapult
    --  Cellular Biomedicine
    --  Cellular Dynamics International
    --  Celularity
    --  Censo Biotechnologies
    --  Center for iPS Cells Research and Application
    --  Centogene
    --  Centre for Commercialization of Regenerative Medicine (CCRM)
    --  Centre for Drug Research and Development (CDRD)
    --  Cesca Therapeutics
    --  Charite-Universitatsmedizin
    --  Children's Hospital Boston
    --  China Cord Blood
    --  China Southeast University
    --  Cincinnati Children's Hospital Medical Center
    --  City of Hope
    --  Clontech Laboratories
    --  Cognate BioServices

    --  and many, many more!

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets

Email This News Email | Submit To Slashdot Slashdot | Submit To Digg | Submit To | News Feeds Feeds

Nav SEOHost.Net: Negative Keywords are Critical for Successful Google Ads Campaigns | Jun 7, 2020
Nav TechSee Wins 'Best Use of AI' Accolade at the Annual Auggie Awards | Jun 7, 2020
Nav Quttera Announces Latest Enhancements to Website Malware Scanner API | Jun 7, 2020
Nav Curriculum Associates Updates i-Ready┬« to Meet Educators' Needs during School Closures and Beyond | Jun 7, 2020
Nav Key Vendor Insights in the Transport Layer Security Certificate Market 2020, Featuring Digicert, Entrust Datacard, Globalsign, Godaddy and Sectigo | Jun 7, 2020
Nav European Mobile Phone Accessories Market to Reach $47.18 Bn, by 2027, at 2.8% CAGR: Allied Market Research | Jun 7, 2020
Nav Impact Global Education Launches Domain, a flexible and affordable higher education solution | Jun 7, 2020
Nav U.S. Retail Recon Software Market to Reach $264.37 Mn, by 2027, at 11.8% CAGR: Allied Market Research | Jun 7, 2020
Nav Asahi Breweries Europe Group Selects GEP SMART(TM) Procurement Software And Goes Live With Source-To-Contract | Jun 7, 2020
Nav Bluestream Health and CommonWealth Purchasing Group Partner to Bring Much-Needed Virtual Care to the Nation's Underserved Population | Jun 7, 2020

Submit News | View More News View More News